Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice

Oncogene volume 21, pages 5934–5939 (2002)Cite this article

Abstract

Apoptosis and long term enterocyte survival were examined in vivo after exposure to three cytotoxic agents (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU)) within mice either singly or doubly mutant for p53 and Msh2. P53 deficiency caused abrogation of the immediate apoptotic response to each agent, but only led to increased survival after cisplatin treatment. Msh2 deficiency reduced the apoptotic response to each agent, but only led to increased crypt survival after NMNU treatment. Following cisplatin treatment, the response of (Msh2−/−, p53−/−) mice paralleled that of the p53−/− mice. A delayed wave of apoptosis was observed in both p53−/− and (Msh2−/−, p53−/−) mice demonstrating this phenomenon to be independent of functional Mismatch repair (MMR). We conclude that loss of either p53 or Msh2 dependent apoptosis does not predict long-term crypt survival in vivo, however genetic status clearly can modulate survival for some agents such as cisplatin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Andrew SE, McKinnon M, Cheng BS, Francis A, Penny J, Reitmar AH, Jirik FR . 1998 Proc. Natl. Acad. Sci. USA 95: 1126–1130

  • Branch P, Masson M, Aquilina G, Bignami M, Karran P . 2000 Oncogene 19: 3138–3145

  • Brown JM, Wouters BG . 1999 Cancer Res. 59: 1391–1399

  • Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, vanderZee AGJ, Anthoney DA . 1997 Oncogene 15: 45–52

  • Bosari S, Viale G . 1995 Virchows Archiv. Int. J. Pathol. 427: 229–241

  • Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH . 1993 Nature 362: 849–852

  • Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH . 1994 Oncogene 9: 1767–1773

  • Clarke AR, Howard LA, Harrison DJ, Winton DJ . 1997 Oncogene 14: 2015–2018

  • DeWeese TL, Shipman JM, Larrier NA, Buckley NM, Kidd LR, Groopman JD, Cutler RG, te Tiele H, Nelson WG . 1998 Proc. Natl. Acad. Sci. USA 95: 11915–11920

  • Duckett DR, Drummond JT, Murchie AIH, Reardon JT, Sancar A, Lilley DM, Modrich P . 1996 Proc. Natl. Acad. Sci. USA 93: 6443–6447

  • Duckett DR, Bronstein SM, Taya Y, Modrich P . 1999 Proc. Natl. Acad. Sci. USA 96: 12384–12388

  • Fink D, Aebi S, Howell SB . 1998 Clin. Cancer Res. 4: 1–6

  • Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP . 1994 Mod. Pathol. 7: 435–439

  • Gong G, Costanzo A, Yang HG, Melino G, Kaelin WG, Levrero M, Wang JYL . 1999 Nature 399: 806–809

  • Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH, Greaves M . 1997 Oncogene 14: 523–531

  • Hendry JH, Cai WB, Roberts SA, Potten CS . 1997 Radiat. Res. 148: 254–259

  • Hemminiki K . 1994 DNA adducts: Identification and biological significance Paris, France: IARC publications pp 313–321

    Google Scholar 

  • Hickman MJ, Samson LD . 1999 Proc. Natl. Acad. Sci. USA 96: 10764–10769

  • Houldsworth J, Xiao H, Murty VVVS, Chen WY, Ray B, Reuter VE, Bosl GJ, Chaganti RSK . 1998 Oncogene 16: 2345–2349

  • Karran P, Bignami M . 1994 Bioessays 16: 833–839

  • Kasparkova J, Pospisilova S, Brabec V . 2001 J. Biol. Chem. 276: 16064–16069

  • Lin XJ, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB . 2001 Cancer Res. 61: 1508–1516

  • Lowe SW, Schmitt EM, Smith SM, Osborne BA, Jacks T . 1993 Nature 362: 847–849

  • Lutzker SG, Levine AJ . 1996 Nat. Med. 2: 804–810

  • Merritt AJ, Allen TS, Potten CS, Hickman JA . 1997 Oncogene 14: 2759–2766

  • Ochs K, Kaina B . 2000 Cancer Res. 60: 5815–5824

  • Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R . 2001 Science 293: 293–297

  • Potten CS . 1990 Int. J. Radiat. Biol. 58: 925–973

  • Potten CS, Hendry JH . 1985 Cell clones: manual of mammalian cell techniques Oxford University, Oxford: IRL press

    Google Scholar 

  • Pritchard DM, Potten CS, Hickman JA . 1998 Cancer Res. 58: 5453–5465

  • Sansom OJ, Clarke AR . 2000 Mutat. Res. 452: 149–162

  • Sansom OJ, Toft NJ, Winton DJ, Clarke AR . 2001 Oncogene 20: 3580–3584

  • Schmitt CA, Rosenthal CT, Lowe SW . 2000 Nat. Med. 6: 1029–1035

  • Strathdee G, MacKean MJ, Illand M, Brown R . 1999 Oncogene 18: 2335–2341

  • Strathdee G, Sansom OJ, Sim A, Clarke AR, Brown R . 2001 Oncogene 20: 1923–1927

  • Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, Riele HT, Arends MJ, Wyllie AH, Margison GP, Clarke AR . 1999 Proc. Natl. Acad. Sci. USA 96: 3911–3915

  • Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310

Download references

Acknowledgements

This work was supported by the Cancer Research UK and the Royal Society. We thank Hein te Riele for supply of the Msh-2 deficient mice.

Author information

Authors and Affiliations

  1. Cardiff School of Biosciences, University of Cardiff, CF10 3US, UK

    Owen J Sansom & Alan R Clarke

  2. Department of Pathology, Teviot Place, University of Edinburgh, EH8 9AG, UK

    Owen J Sansom

Authors
  1. Owen J Sansom
    View author publications

    Search author on:PubMed Google Scholar

  2. Alan R Clarke
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Alan R Clarke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sansom, O., Clarke, A. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21, 5934–5939 (2002). https://doi.org/10.1038/sj.onc.1205760

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1205760

Keywords

This article is cited by

Search

Advanced search

Quick links